Company: Elucida Oncology Inc.
Job title: Chief Scientific Officer
Broadening Therapeutic Indications to Cancers with Lower Target Antigen Expression with C’Dot Drug Conjugates 10:30 am
Unveiling C’Dot Drug Conjugates (CDCs) as a platform technology that is associated with specific tumor targeting/low normal tissue exposure Showcasing the exciting potential of CDCs in targeting and killing tumors with lower antigen expression than is normally possible with ADCs Unpacking clinical efficacy and safety data from the safety/dose escalation study of ELU001, in addition…Read more
day: Conference Day Two